Name: IMMUNOVANT INC (IMVT) Stock
Brand: IMMUNOVANT INC
Rating: 6.5 (3 reviews)

IMVT Latest News, Press Relases and Analysis

All

Press Releases

10 days ago - By: Chartmill

Immunovant Inc (NASDAQ:IMVT) Stock Falls 10% on Q2 FY2026 Earnings and Corporate Updates

9 days ago - By: Zacks Investment Research - Mentions: ALKS FOLD CRMD

Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus

10 days ago - By: Immunovant Inc.

Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025

10 days ago - By: Benzinga - Mentions: CNC NVO PFE QURE ...

Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session

21 days ago - By: Benzinga - Mentions: GH GKOS VIAV XPO ...

Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursday

24 days ago - By: Immunovant Inc.

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

2 months ago - By: Kahn Swick & Foti, LLC

IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

2 months ago - By: Kahn Swick & Foti, LLC

IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

2 months ago - By: Zacks Investment Research - Mentions: ALKS

Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue?

3 months ago - By: Zacks Investment Research - Mentions: CRMD KNSA PHAR

IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results

3 months ago - By: The Motley Fool

Why Immunovant Stock Blasted Higher Today

3 months ago - By: Immunovant Inc.

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

3 months ago - By: Yahoo Finance - Mentions: ROIV

Roivant Sciences (ROIV) Announces Q1 2025 Business Update

3 months ago - By: The Schall Law Firm

IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm

3 months ago - By: Kahn Swick & Foti, LLC

IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

3 months ago - By: Zacks Investment Research - Mentions: CRMD ZYME ALVO

Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus

3 months ago - By: The Motley Fool

Immunovant Posts 34% R&D Jump in Q1

3 months ago - By: Immunovant Inc.

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025

4 months ago - By: Zacks Investment Research

All You Need to Know About Immunovant (IMVT) Rating Upgrade to Buy

4 months ago - By: Zacks Investment Research

Wall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High?

5 months ago - By: Yahoo Finance

LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT

5 months ago - By: ACCESS Newswire

IMVT INVESTIGATION ALERT: Pittsburgh Law Office of Alfred G. Yates Jr. PC Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm

6 months ago - By: Zacks Investment Research

Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock?

6 months ago - By: Zacks Investment Research - Mentions: LXRX AMRN

IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus

6 months ago - By: Robbins Geller Rudman & Dowd LLP

IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm

6 months ago - By: Stocktwits - Mentions: VTI XBI

Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence

6 months ago - By: Immunovant Inc.

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025

6 months ago - By: Yahoo Finance - Mentions: ROIV UBS WLK TRML ...

H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock

6 months ago - By: Yahoo Finance - Mentions: UBS WLK ROIV DHI ...

UBS Lowers Price Target on Westlake (WLK), Keeps Buy Rating

6 months ago - By: Yahoo Finance - Mentions: TRML ROIV DHI CMG

H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results

6 months ago - By: Robbins Geller Rudman & Dowd LLP

IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm

7 months ago - By: Investor's Business Daily - Mentions: ROIV

IMMUNOVANT INC (IMVT) Stock News

IMVT Latest News, Press Relases and Analysis

Immunovant Inc (NASDAQ:IMVT) Stock Falls 10% on Q2 FY2026 Earnings and Corporate Updates

Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus

Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025

Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursday

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue?

IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results

Why Immunovant Stock Blasted Higher Today

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

Roivant Sciences (ROIV) Announces Q1 2025 Business Update

IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm

IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus

Immunovant Posts 34% R&D Jump in Q1

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025

All You Need to Know About Immunovant (IMVT) Rating Upgrade to Buy

Wall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High?

LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT

IMVT INVESTIGATION ALERT: Pittsburgh Law Office of Alfred G. Yates Jr. PC Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm

Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock?

IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus

IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm

Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025

H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock

UBS Lowers Price Target on Westlake (WLK), Keeps Buy Rating

H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results

IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm

Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift